Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alector Inc

ALEC
Current price
5.49 USD 0 USD (0.00%)
Last closed 5.62 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 467 798 368 USD
Yield for 12 month -40.78 %
Week
Month
Year
ALEC
21.11.2021 - 28.11.2021

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California. Address: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Analytics

WallStreet Target Price

13.56 USD

P/E ratio

Dividend Yield

Current Year

+133 617 000 USD

Last Year

+207 085 000 USD

Current Quarter

+9 109 000 USD

Last Quarter

+56 214 000 USD

Current Year

+133 617 000 USD

Last Year

+207 085 000 USD

Current Quarter

+9 109 000 USD

Last Quarter

+56 214 000 USD

Key Figures ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -154 043 008 USD
Operating Margin TTM -555.31 %
PE Ratio
Return On Assets TTM -13.23 %
PEG Ratio
Return On Equity TTM -68.03 %
Wall Street Target Price 13.56 USD
Revenue TTM 96 312 000 USD
Book Value 1.93 USD
Revenue Per Share TTM 1.16 USD
Dividend Share
Quarterly Revenue Growth YOY -38.7 %
Dividend Yield
Gross Profit TTM -76 801 000 USD
Earnings Share -1.71 USD
Diluted Eps TTM -1.71 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -86.3 %
Profit Margin -146.8 %

Dividend Analytics ALEC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 526.3158
Enterprise Value Revenue 0.4647
Price Sales TTM 4.8571
Enterprise Value EBITDA 0.5241
Price Book MRQ 2.8881

Financials ALEC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ALEC

For 52 weeks

3.66 USD 9.86 USD
50 Day MA 5.52 USD
Shares Short Prior Month 7 675 174
200 Day MA 6.52 USD
Short Ratio 12.16
Shares Short 7 152 828
Short Percent 11.26 %